high5immunology.tv | Rheumatology | EULAR 2021

Spotlight Discussion

EULAR 2021

Early detection of PsA & patient stratification

F. Behrens, P. Sewerin, A. Askari, V. Goëb, E. Lubrano

EULAR 2021

Update GRAPPA recommendations & axial PsA vs axSpA

F. Behrens, P. Sewerin, A. Askari, V. Goëb, E. Lubrano

EULAR 2021

Treatment decissions and therapeutic options in PsA

F. Behrens, P. Sewerin, A. Askari, V. Goëb, E. Lubrano

EULAR 2021

RA treatment - status and perspectives

P. Sewerin, F. Behrens, T. Kvien, E. Choy, A. Balsa

EULAR 2021

Early detection and treatment of RA

P. Sewerin, F. Behrens, T. Kvien, E. Choy, A. Balsa

EULAR 2021

Difficult to treat RA - hot topics and challenges

P. Sewerin, F. Behrens, T. Kvien, E. Choy, A. Balsa

Rheumatoid arthritis – ENG

EULAR 2021

Switching of treatment from reference etanercept to…

Ayman Askari, MD

EULAR 2021

JAKi in real life!

Vincent Goëb, MD,PhD

EULAR 2021

Vitamin D level in response to biologics

Vincent Goëb, MD, PhD

EULAR 2021

RA activity and risk of complications after…

Vincent Goëb, MD, PhD

EULAR 2021

Recurrence of joint inflammation

Vincent Goëb, MD, PhD

EULAR 2021

Using anti-TNF to deliver corticosteroids to…

Ernest Choy, MD

EULAR 2021

Clinical outcome after switching between IL-6 and JAK…

Ernest Choy, MD

EULAR 2021

Interstitial lung disease in patients with RA

Tore Kvien, MD

EULAR 2021

Risk of cardiovascular events and disease activity

Tore Kvien, MD

EULAR 2021

Influence of comorbitidy on mortality

Tore Kvien, MD

EULAR 2021

Passive smoking in childhood and adulthood increases…

Alejandro Balsa, MD, PhD

EULAR 2021

Definition of difficult to treat rheumatoid arthritis

Alejandro Balsa, MD, PhD

Rheumatoid arthritis – FRA/ESP/NOR

EULAR 2021

JAKi dans la vraie vie!

Vincent Goëb, MD, PhD

EULAR 2021

Vitamine D et réponse aux biomédicaments

Vincent Goëb, MD, PhD

EULAR 2021

Complications après arthroplastie selon l’activité du…

Vincent Goëb, MD, PhD

EULAR 2021

Où les arthrites récidivent-elles?

Vincent Goëb, MD, PhD

EULAR 2021

Interstitiell lungesykdom hos pasienter med RA

Tore Kvien, MD

EULAR 2021

Risiko for kardiovaskulære hendelser og…

Tore Kvien, MD

EULAR 2021

Påvirkning av komorbiditeter på mortalitet

Tore Kvien, MD

EULAR 2021

El tabaquismo pasivo aumenta el riesgo de padecer una…

Alejandro Balsa, MD, PhD

EULAR 2021

Definición de artritis reumatoide difícil de tratar

Alejandro Balsa, MD, PhD

Psoriatic arthritis – ENG

EULAR 2021

Cardiovascular risk and metabolomic profiling in PsA

Frank Behrens, MD

EULAR 2021

Deucravacitinib (TYK2 Inhibitor) in Psoriasis and…

Frank Behrens, MD

EULAR 2021

Secukinumab: Adherence in PsA and AS

Frank Behrens, MD

EULAR 2021

Hyperuricemia: increased risk of severe PsA course

Philipp Sewerin, MD, PD

EULAR 2021

Power-Doppler ultrasound of the achilles tendon to…

Philipp Sewerin, MD, PD

EULAR 2021

GRAPPA Recommendations 2021

Philipp Sewerin, MD, PD

EULAR 2021

Faeceal microbiota transplantation

Philipp Sewerin, MD, PD

EULAR 2021

Role of Sex and Weight on PsA

Philipp Sewerin, MD, PD

Psoriatic arthritis – GER

EULAR 2021

Kardiovaskuläres Risiko und metabolomisches Profil bei…

Frank Behrens, MD

EULAR 2021

Deucravacitinib (TYK 2 Inhibitor) neu bei PsA und…

Frank Behrens, MD

EULAR 2021

Secukinumab: Adhärenz bei PsA and AS

Frank Behrens, MD

EULAR 2021

Cave Hyperurikämie: Erhöhtes Risiko für schweren…

Philipp Sewerin, MD, PD

EULAR 2021

Power-Doppler-Sono AS: Differenzierung Belastung vs.…

Philipp Sewerin, MD, PD

EULAR 2021

GRAPPA Empfehlungen 2021

Philipp Sewerin, MD, PD

EULAR 2021

Rolle von Geschlecht und Gewicht

Philipp Sewerin, MD, PD

Axial spondyloarthritis – ENG

EULAR 2021

Radiographic progression in axSpA

Xabier Michelena Vegas, MD

EULAR 2021

Do patients with axSpA help us?

Xabier Michelena Vegas, MD

EULAR 2021

Feasibilty of anti-TNF tapering in low disease…

Francesco Ciccia, MD, PhD

EULAR 2021

Impact of sex on BASDAI scores

Francesco Ciccia, MD, PhD

EULAR 2021

Non-radiographic or radiographic axial SpA - does it…

Ayman Askari, MD

Axial spondyloarthritis – ESP/ITA

EULAR 2021

Impatto del sesso sugli score del BASDAI

Francesco Ciccia, MD, PhD

EULAR 2021

fattibilità della riduzione del dosaggio degli anti-TNF…

Francesco Ciccia, MD, PhD

EULAR 2021

¿Nos ayudan los pacientes con espondiloartritis axial?

Xabier Michelena Vegas, MD

EULAR 2021

Progresión radiográfica en espondiloartritis axial

Xabier Michelena Vegas, MD

COVID-19 – ENG

EULAR 2021

COVID-19 outcome in inflammatory arthropathy patients

Ayman Askari, MD

EULAR 2021

COVID-19 Vaccination in patients with rheumatic disease

Bimba Franziska Hoyer, MD

EULAR 2021

Rituximab and COVID-19 (Multicenter-Study)

Bimba Franziska Hoyer, MD

EULAR 2021

Rituximab and COVID-19 (Nat. French Registry Study)

Bimba Franziska Hoyer, MD

EULAR 2021

Influence of TNF-Inhibition on COVID-19

Bimba Franziska Hoyer, MD

EULAR 2021

Risk factors of COVID-19 course in SLE

Bimba Franziska Hoyer, MD

EULAR 2021

Immunogenicity of mRNA-COVID-19 vaccine in patients…

Alejandro Balsa, MD, PhD

EULAR 2021

Outcome of Covid-19 in Rheumatoid Arthritis under…

Ernest Choy, MD

COVID-19 – ESP/GER

EULAR 2021

Patientenumfrage während der Pandemie

Bimba Franziska Hoyer, MD

EULAR 2021

Rituximab bei COVID-19 (Multicenter-Studien)

Bimba Franziska Hoyer, MD

EULAR 2021

Rituximab bei COVID-19 (franz. Registerdaten)

Bimba Franziska Hoyer, MD

EULAR 2021

Einfluss von TNF-Blockern auf COVID-19-Verlauf

Bimba Franziska Hoyer, MD

EULAR 2021

COVID-19 bei SLE

Bimba Franziska Hoyer, MD

EULAR 2021

Immunogenicidad de la vacuna mRNA-COVID-19 en pacientes…

Alejandro Balsa, MD, PhD

EULAR

SARS-CoV2-Impfung bei Rheumapatienten

Bimba Franziska Hoyer, MD

Lupus erythematosus – ENG

EULAR 2021

Combination of Belimumab and Rituximab is beneficial

Bimba Franziska Hoyer, MD

EULAR 2021

Convincing Anifrolumab data on efficacy and drug…

Bimba Franziska Hoyer, MD

EULAR 2021

New therapy for cutaneous manifestations

Bimba Franziska Hoyer, MD

Lupus erythematosus – GER

EULAR 2021

Kombination Belimumab und Retuximab vorteilhaft

Bimba Franziska Hoyer, MD

EULAR 2021

Anifrolumab in Wirksamkeit und Verträglichkeit…

Bimba Franziska Hoyer, MD

EULAR 2021

Neue Therapie für kutane Manifestationen

Bimba Franziska Hoyer, MD

Vasculitis – ENG

EULAR 2021

Ultrasound halo sign as a potential monitoring tool for…

Ayman Askari, MD

EULAR 2021

What is new in Giant Cell Arteritis?

Ayman Askari, MD

EULAR 2021

Efficcacy and Safety of TNF-α Blockers and Tocilizumab…

Carlo Salvarani, MD

EULAR 2021

Tocilizumab Monotherapy for Giant Cell Arteritis - the…

Carlo Salvarani, MD

Vasculitis – ITA

EULAR 2021

Monoterapia con tocilizumab nella arterite a cellule…

Carlo Salvarani, MD

EULAR 2021

Efficacia e sicurezza degli anti-TNF e del tocilizumab…

Carlo Salvarani, MD

Systemic sclerosis – ENG

EULAR 2021

Lung involvement: diagnostic work-up and  new treatment…

Ayman Askari, MD

Varia – ENG

EULAR 2021

Risk factors for ADAb formation: Data from the NOR-DRUM…

Alejandro Balsa, MD, PhD

EULAR 2021

Therapeutic drug monitoring and immunogenicity

Tore Kvien, MD

EULAR 2021

Fatigue in Arthritis, SpA & systemic rheumatic diseases

Ayman Askari, MD

EULAR 2021

Lyme disease: Myths and reality

Ayman Askari, MD

EULAR 2021

Secukinumab in patients with rotator cuff tendinopathy

Ayman Askari, MD

Varia – POL/ESP/NOR

EULAR 2021

Co nowego w reumatologii dziecięcej

Zbigniew Zuber, MD, PhD

EULAR 2021

Therapeutic drug monitoring (TDM) og immunogenisitet

Tore Kvien, MD

EULAR 2021

Factores de riesgo del desarrollo de anticuerpos…

Alejandro Balsa, MD, PhD

EULAR 2021

EULAR, najnowsze postępy w reumatologii

Zbigniew Zuber, MD, PhD